Login
Scholar Rock Holding Corp logo

Scholar Rock Holding Corp

scholarrock.com

What Do They Do?

Develops antibody medicines that target growth factors for people with spinal muscular atrophy and other rare neuromuscular diseases.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
vs $0 in Q3 FY2025
Net income
▼ −5% (Loss)
vs −$102.2M in Q3 FY2025
  • Sep 11, 2026 FDA approves ISEMBYLD for spinal muscular atrophy The approval covers adults and children receiving an SMN2-targeted treatment; the U.S. commercial launch is underway.

Portfolio focus The portfolio has shifted from programs spanning neuromuscular disease, cancer, fibrosis and iron-restricted anemia toward a rare-neuromuscular focus; the company is seeking partners for its cancer, fibrosis and anemia programs.

Who Do They Compete With?

Competes with Roche, Biogen, NMD Pharma, Novartis, AbbVie, Bicara Therapeutics, Bristol Myers Squibb, and Merck

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support